Literature DB >> 8871618

Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes.

C C Bergmann1, Q Yao, C K Ho, S L Buckwold.   

Abstract

CD8+ CTL responses constitute a critical component for vaccines developed to eliminate intracellular pathogens. One approach to achieve broad CTL diversity is based on genetically linking immunogenic peptides from multiple proteins to form poly-epitope Ags. To address the influence of flanking residues on class I Ag presentation, H-2d-restricted HIV-1 and mouse hepatitis virus CTL epitopes were linked via various spacer residues. The resulting 20 to 31 amino acid peptides were expressed using recombinant vaccinia viruses to monitor both CTL recognition and induction. Our data indicate that recognition is profoundly influenced by the nature of intervening residues forming carboxyl-terminal flanks for one and amino-terminal flanks for the other epitope. Flanking amino acids with aromatic (tyrosine), basic (lysine), and small aliphatic side chains (alanine) supported efficient CTL recognition of both epitopes. By contrast, acidic and helix breaking residues (glycine, proline) specifically inhibited recognition of the adjacent amino-terminal epitope. Flanking residues inhibitory for recognition were also detrimental for CTL induction, suggesting similar processing mechanisms in vitro and in vivo. The ratios of peptide-specific CTL precursors primed by the tandem epitopes varied up to 50-fold depending on molecular context. These data demonstrate a substantial role of carboxyl-flanking residues in governing the efficiency of class I Ag presentation both in vitro and in vivo. The dramatic influence of flanking residues on the hierarchy of CTL responses indicates that CTL induction by poly-epitope Ags can be optimized by strategically linking epitopes via selection of appropriate spacer residues.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8871618

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

1.  Mimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivo.

Authors:  Yu-Zhang Wu; Jian-Ping Zhao; Ying Wan; Zheng-Cai Jia; Wei Zhou; Jiang Bian; Bing Ni; Li-Yun Zou; Yan Tang
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development.

Authors:  H Cao; P Kanki; J L Sankalé; A Dieng-Sarr; G P Mazzara; S A Kalams; B Korber; S Mboup; B D Walker
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.

Authors:  Lawrence M Mylin; Todd D Schell; Melanie Epler; Caroline Kusuma; David Assis; Chelsea Matsko; Alexandra Smith; April Allebach; Satvir S Tevethia
Journal:  Virology       Date:  2007-03-21       Impact factor: 3.616

4.  Identification of a 17beta-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide.

Authors:  Ronald C Hendrickson; Vito R Cicinnati; Andreas Albers; Grzegorz Dworacki; Andrea Gambotto; Ornella Pagliano; Thomas Tüting; Jose I Mayordomo; Carmen Visus; Ettore Appella; Jeffrey Shabanowitz; Donald F Hunt; Albert B DeLeo
Journal:  Cancer Immunol Immunother       Date:  2009-06-27       Impact factor: 6.968

5.  The effect of adjuvanting cancer vaccines with herpes simplex virus glycoprotein D on melanoma-driven CD8+ T cell exhaustion.

Authors:  Ying Zhang; Hildegund C J Ertl
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

6.  Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences.

Authors:  C Brander; O O Yang; N G Jones; Y Lee; P Goulder; R P Johnson; A Trocha; D Colbert; C Hay; S Buchbinder; C C Bergmann; H J Zweerink; S Wolinsky; W A Blattner; S A Kalams; B D Walker
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope.

Authors:  T M Fu; L M Mylin; T D Schell; I Bacik; G Russ; J W Yewdell; J R Bennink; S S Tevethia
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

8.  Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C.

Authors:  V Novitsky; H Cao; N Rybak; P Gilbert; M F McLane; S Gaolekwe; T Peter; I Thior; T Ndung'u; R Marlink; T H Lee; M Essex
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

Review 9.  TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy.

Authors:  Roberto Bei; Antonio Scardino
Journal:  J Biomed Biotechnol       Date:  2010-06-17

10.  Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.

Authors:  Luciana M Silva-Flannery; Monica Cabrera-Mora; Jianlin Jiang; Alberto Moreno
Journal:  Microbes Infect       Date:  2008-10-26       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.